SNG-12, also known as Synapsinae, is a glycine transporter 1 (GlyT1) inhibitor, or a glycine reuptake inhibitor, which is under development for the treatment of psychotic disorders, dementia, depressive disorders, and suicidal ideation.[1][2][3] As of September 2022, it is in phase 3 clinical trials for depressive disorders and suicidal ideation and is in phase 2 clinical rials for psychotic disorders and dementia.[1][2][3] The drug is under development by SyneuRx.[1][2] It is described as a small molecule, but its chemical structure does not appear to have been disclosed.[1][2][4]
| Clinical data | |
|---|---|
| Other names | SNG12; SNG 12; Synapsinae |
| Drug class | Glycine transporter 1 (GlyT1) inhibitor; Glycine reuptake inhibitor |
See also
editReferences
edit- ^ a b c d "SNG 12". AdisInsight. 23 September 2022. Retrieved 21 October 2024.
- ^ a b c d "Delving into the Latest Updates on Synapsinae with Synapse". Synapse. 28 September 2024. Retrieved 21 October 2024.
- ^ a b "A phase III study for SNG-12 in depression and Suicidal ideation". AdisInsight. 16 March 2021. Retrieved 21 October 2024.
- ^ "Synapsinae Drug Profile". Ozmosi. 7 May 2024. Retrieved 21 October 2024.
 | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |